1) dual inhibitors of COX and 5-LOX
COX/5-LOX双重抑制剂
2) selective 5-LOX/COX-2 dual inhibitors
选择性5-LOX/COX-2双重抑制剂
1.
Many new NSAIDs have being come into market, such as selective COX-2 inhibitors, NO-releasling NSAIDs, selective 5-LOX/COX-2 dual inhibitors.
本文主要综述了选择性COX-2抑制剂、一氧化氮释放型非甾体抗炎药以及选择性5-LOX/COX-2双重抑制剂三类非甾体抗炎药中的代表药物的研究进展。
3) COX/5-LO dual inhibitors
COX/5-LO双重抑制剂
1.
AIM: searching for the relationship between biological activities and structure of COX/5-LO dual inhibitors in order to design new COX/5-LO dual inhibitors.
目的:寻找COX/5-LO双重抑制剂的生物活性与化学结构之间的关系,为设计合成新型COX/5-LO双重抑制剂提供理论依据。
5) COX-2 inhibitor
COX-2抑制剂
1.
Preparation of selective COX-2 inhibitor NS-398;
选择性COX-2抑制剂NS-398的制备
2.
Improved synthesis of the COX-2 inhibitor celecoxib;
COX-2抑制剂celecoxib的合成工艺改进
3.
Clinical application of COX-2 inhibitors;
COX-2抑制剂的临床应用
6) COX-2 inhibitors
COX-2抑制剂
1.
Safety Assessment of Selective COX-2 Inhibitors;
选择性COX-2抑制剂的安全性评估
2.
Combination therapy of α-blockers, COX-2 inhibitors and antidepressive drug in the treatment of chronic prostatitis/chronic pelvic pain syndrome
α-受体阻滞剂、COX-2抑制剂和抗抑郁药联合治疗慢性前列腺炎/慢性盆底疼痛综合征
3.
This was based on 3 long term randomize control clinical trials of two COX-2 inhibitors(Rofecoxib and Celecoxib),which showed, unexpectly,that CV events occurred more than 1 1/2 years later.
为保证患者的安全,美国FDA发布使用COX-2抑制剂及非甾体抗炎药(NSAID)的声明,要求修改所有NSAID(包括COX-2抑制剂)的说明书,增加该类药物可增加心血管及胃肠道事件风险的黑框警告。
补充资料：[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式：C16H16ClN3O3S
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条